Orthocell (OCC) Company presentation summary

Financial performance and revenue growth

• FY24 revenue reached $6.76 million, a 30.76% increase from FY23, with a CAGR of 93% over recent years.

• Strong 1Q FY25 performance is ahead of expectations, driven by Striate+ and Remplir products.

• No debt and $20.6 million cash at bank, funding operations beyond US Remplir approval.

Product portfolio and innovation

• Collagen-based medical devices address bone, nerve, tendon, and cartilage repair.

• Striate+ dental membrane and Remplir nerve wrap are revenue-generating and approved in multiple jurisdictions.

• Remplir offers improved nerve repair outcomes, with 85% of clinical cases showing functional recovery.

Market expansion and regulatory milestones

• Remplir is approved in Australia and New Zealand, with US approval expected in 1Q CY25 and Singapore in 2H CY24.

• Striate+ is approved in the US, EU/UK, Australia, and Canada, with expansion into Brazil and Singapore underway.

• Large addressable markets: $3.5 billion for nerve repair and $732 million for dental membranes.